Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio
Details : Under the licensing agreement, RayzeBio will hold the rights to develop, manufacture, and commercialise 68-Ga OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer.
Product Name : 68-Ga OncoACP3
Product Type : Radiolabelled Compounds
Upfront Cash : $350.0 million
June 10, 2025